Chronic lymphocytic leukemia (CLL) treatment in Istanbul, Turkey
Chronic lymphocytic leukemia is a slow-growing cancer of mature B lymphocytes, often found on a routine blood test. What makes it distinct: many patients are watched before any treatment — early treatment doesn’t help — and modern therapy is largely targeted oral drugs, not chemotherapy. When treatment is needed, BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and the BCL-2 inhibitor venetoclax, often with an anti-CD20 antibody, do most of the work. Prognostic testing (TP53/17p, IGHV) guides drug choice. Istanbul hospitals offer this full pathway, often at JCI-accredited, state-authorized centers and well below Western-European prices. Every price we show is an illustrative placeholder until verified partner-hospital quotes exist — and you pay the hospital directly, never us. Start with a free 72-hour review of your reports before you decide anything.
What chronic lymphocytic leukemia is
The U.S. National Cancer Institute describes chronic lymphocytic leukemia (CLL) as a slow-growing blood and bone-marrow cancer in which the body makes too many abnormal mature B lymphocytes, a type of white blood cell. Because it usually progresses slowly, the NCI notes it often causes no symptoms early on and is frequently found by chance on a routine blood test that shows a high lymphocyte count. When symptoms do appear they can include swollen but painless lymph nodes, fatigue, fever or night sweats, and an enlarged spleen.
Diagnosis is confirmed with blood tests and flow cytometry, and a bone marrow examination may be done. What sets CLL apart from faster leukemias is that prognostic testing drives the plan: the NCI highlights TP53 mutation or 17p deletion and IGHV mutation status, which predict how the disease will behave and which drugs will work. Browse the wider cancer types hub for related diagnoses.
Treatment options
The approaches the NCI lists for CLL, and an honest note on each:
- Active surveillance (watch and wait). For early, symptom-free disease the standard is to monitor rather than treat, because the NCI notes early treatment does not lengthen life. Therapy begins only when there are signs of progression — this is the option many CLL patients stay on for years.
- Targeted oral therapy. The modern backbone once treatment is needed: BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and the BCL-2 inhibitor venetoclax, often paired with an anti-CD20 monoclonal antibody such as obinutuzumab or rituximab. See how targeted therapy and immunotherapy work in general.
- Chemoimmunotherapy. Older combinations of chemotherapy with an antibody are used less often now, but still fit selected cases — usually younger patients with favourable IGHV status. Which applies is decided by your prognostic testing, not a template.
- Stem cell transplant. A stem cell (bone marrow) transplant is reserved for rare, high-risk or relapsed disease that no longer responds to targeted drugs. It is the intensive end of the pathway, not a routine step.
See how these modalities work in general on the treatments & technology hub.
What it costs
There is no single CLL price, because much of the cost is the targeted drugs themselves— BTK inhibitors and venetoclax are priced per month or per cycle and can dominate the total, while a watch-and-wait patient may pay only for monitoring for years before any treatment begins. The number of cycles, whether an anti-CD20 antibody is added, and the rare need for a transplant all move the figure. Every number OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, and each is itemized so you can hold a real quote up against it line by line. See the Turkey Oncology Price Index or the full cancer treatment cost in Turkey breakdown.
The hospital, verified
We don’t show a wall of smiling hematologists or a “ranked” list — those are the easiest things to fabricate. Instead, you’re matched to one state-authorized Istanbul partner hospital whose hematology and hemato-oncology subspecialty fits your diagnosis, and you can verify its authorization against the Republic of Turkey Ministry of Health’s own records and its JCI accreditation in JCI’s public directory before you commit. Named specialist profiles appear only when a verified, consented physician is behind the name. See the full guide to cancer hospitals in Istanbul and how to check one yourself.
Where this fits
CLL is one subtype within the broader leukemia treatment in Turkey overview, which itself sits under the cancer treatment in Istanbul pillar. If you want your own reports read first, a free second opinion organizes and verifies your blood work, flow cytometry and prognostic testing into a plain-language case file in your language before you decide whether to travel.
Related cancers
Check everything here — us included
Common questions
Can I get CLL treatment in Turkey?
Yes. Istanbul hospitals provide the full chronic lymphocytic leukemia pathway the U.S. National Cancer Institute describes — active surveillance for early, symptom-free disease, targeted oral therapy with BTK inhibitors such as ibrutinib, acalabrutinib or zanubrutinib, the BCL-2 inhibitor venetoclax often paired with an anti-CD20 antibody like obinutuzumab, chemoimmunotherapy in selected cases, and stem cell transplant reserved for rare high-risk disease. Many centers hold JCI accreditation and Turkish Ministry of Health state authorization, both of which you can check yourself before you commit. The honest first step is a free case review of your blood work, flow cytometry and prognostic testing so the plan is understood before you travel.
Why do doctors sometimes watch and wait with CLL?
Because starting treatment early does not help. The NCI is explicit that for CLL found early and causing no symptoms, active surveillance — often called watch and wait — is standard, and studies show treating before symptoms appear does not lengthen life. So the team monitors blood counts and how you feel, and begins therapy only when there are signs the disease is progressing, such as falling blood counts, growing lymph nodes or an enlarging spleen. It can feel counterintuitive to leave a cancer untreated, but for many people with CLL it is the evidence-based choice. This is general information, not a treatment recommendation.
What are BTK inhibitors and venetoclax?
They are the targeted oral drugs that now anchor CLL treatment. Per the NCI, BTK inhibitors — ibrutinib, acalabrutinib and zanubrutinib — block a signalling protein that CLL cells depend on to survive, and venetoclax blocks BCL-2, a protein that keeps those cells from dying. Both are often combined with an anti-CD20 monoclonal antibody such as obinutuzumab or rituximab. Unlike older chemoimmunotherapy, these are precise drugs taken by mouth. Which one fits depends on your prognostic testing — particularly TP53 mutation or 17p deletion and IGHV mutation status — which a case review will flag on your reports.
How much does CLL treatment cost in Istanbul?
There is no single figure, because much of the cost of chronic lymphocytic leukemia care is the targeted drugs themselves — BTK inhibitors and venetoclax are priced per month or per cycle and can dominate the total, and a watch-and-wait patient may pay only for monitoring for years before any treatment begins. The number of cycles, whether an anti-CD20 antibody is added, and rare cases needing a transplant all move the figure. Istanbul typically runs well below Western-European prices for the same protocol, but every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, itemized so you can check a real written quote line by line. You pay the hospital directly, never us.
Start with a free 72-hour case review
Send your blood work and reports. Get a verified case file in your language — free, confidential, no obligation.
This page is general information, not medical advice. Medical facts are grounded in the U.S. National Cancer Institute; prices shown are illustrative placeholders pending verified partner-hospital quotes, not offers. Every cancer case is individual; assessments are based on the reports you provide and do not replace in-person examination.